EP
SNDX icon

Essential Partners’s Syndax Pharmaceuticals SNDX Stock Holding History

Essential Partners’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.1K Sell
598
-849
-59% -$17.7K 0.01% 1089
2026
Q1 		$33.8K Sell
1,447
-8
-0.5% -$174 0.01% 721
2025
Q4 		$30.6K Buy
1,455
+532
+58% +$9.28K 0.01% 760
2025
Q3 		$14.2K Buy
+923
New +$12.1K ﹤0.01% 1027

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Essential Partners's SNDX Position: Q2 2026 in Review

Essential Partners reduced its Syndax Pharmaceuticals (SNDX) stake by 59% in Q2 2026, selling an estimated $17.7K and leaving 598 shares worth $13.1K. The position accounts for 0.01% of the portfolio, ranked #1089.

Essential Partners first reported a position in SNDX in Q3 2025 and has held it in 4 quarters since. The position peaked at $33.8K in Q1 2026. 242 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Essential Partners held 598 shares of Syndax Pharmaceuticals worth $13.1K as of Q2 2026.
  • Essential Partners sold 849 Syndax Pharmaceuticals shares in Q2 2026, an estimated $17.7K.
  • Syndax Pharmaceuticals made up 0.01% of Essential Partners's portfolio in Q2 2026, its #1089 holding.
  • Essential Partners first reported a position in Syndax Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Essential Partners's Syndax Pharmaceuticals position peaked at $33.8K in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.